The role of interferons type I, II and III in myositis: A review - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Brain Pathology Année : 2021

The role of interferons type I, II and III in myositis: A review

Résumé

The classification of idiopathic inflammatory myopathies (IIM) is based on clinical, serological and histological criteria. The identification of myositis-specific antibodies has helped to define more homogeneous groups of myositis into four dominant subsets: dermatomyositis (DM), antisynthetase syndrome (ASyS), sporadic inclusion body myositis (sIBM) and immune-mediated necrotising myopathy (IMNM). sIBM and IMNM patients present predominantly with muscle involvement, whereas DM and ASyS patients present additionally with other extramuscular features, such as skin, lung and joints manifestations. Moreover, the pathophysiological mechanisms are distinct between each myositis subsets. Recently, interferon (IFN) pathways have been identified as key players implicated in the pathophysiology of myositis. In DM, the key role of IFN, especially type I IFN, has been supported by the identification of an IFN signature in muscle, blood and skin of DM patients. In addition, DM-specific antibodies are targeting antigens involved in the IFN signalling pathways. The pathogenicity of type I IFN has been demonstrated by the identification of mutations in the IFN pathways leading to genetic diseases, the monogenic interferonopathies. This constitutive activation of IFN signalling pathways induces systemic manifestations such as interstitial lung disease, myositis and skin rashes. Since DM patients share similar features in the context of an acquired activation of the IFN signalling pathways, we may extend underlying concepts of monogenic diseases to acquired interferonopathy such as DM. Conversely, in ASyS, available data suggest a role of type II IFN in blood, muscle and lung. Indeed, transcriptomic analyses highlighted a type II IFN gene expression in ASyS muscle tissue. In sIBM, type II IFN appears to be an important cytokine involved in muscle inflammation mechanisms and potentially linked to myodegenerative features. For IMNM, currently published data are scarce, suggesting a minor implication of type II IFN. This review highlights the involvement of different IFN subtypes and their specific molecular mechanisms in each myositis subset.
Fichier principal
Vignette du fichier
bpa.12955.pdf (494.17 Ko) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

hal-03242856 , version 1 (31-05-2021)

Identifiants

Citer

Loïs Bolko, Wei Jiang, Nozomu Tawara, Océane Landon-Cardinal, Céline Anquetil, et al.. The role of interferons type I, II and III in myositis: A review. Brain Pathology, 2021, 31 (3), pp.e12955. ⟨10.1111/bpa.12955⟩. ⟨hal-03242856⟩
48 Consultations
447 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More